Mr. Singh joined our Board of Directors in 2000 and our management team in 2003 following our acquisition of Artemis Neuroscience, of which he was President. Mr. Singh has nearly 20 years of experience working with biopharmaceutical companies. He currently serves as Managing Principal of Cato BioVentures, a life science venture capital firm affiliated with Cato Research, a leading contract research organization. Mr. Singh also serves in management and director roles for Echo Therapeutics and Hemodynamic Therapeutics, each a Cato BioVentures portfolio company. Mr. Singh served as Chief Business Officer of SciClone Pharmaceuticals (Nasdaq: SCLN) and as a Corporate Finance Associate of Morrison & Foerster, an international law firm. Mr. Singh is a member of the State Bar of California.
